Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
CDK7 inhibitor
DRUG CLASS:
CDK7 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
YPN-005 (7)
SY‑079 (4)
SY-5609 (3)
CT7001 (3)
TG02 (2)
BTX-A51 (1)
KRLS-017 (1)
Q901 (1)
AUR102 (0)
EOC237 (0)
GTAEXS617 (0)
LY3405105 (0)
TGN-1062 (0)
TY-2699a (0)
XNW9015 (0)
SY-1365 (0)
CYC202 (0)
YPN-005 (7)
SY‑079 (4)
SY-5609 (3)
CT7001 (3)
TG02 (2)
BTX-A51 (1)
KRLS-017 (1)
Q901 (1)
AUR102 (0)
EOC237 (0)
GTAEXS617 (0)
LY3405105 (0)
TGN-1062 (0)
TY-2699a (0)
XNW9015 (0)
SY-1365 (0)
CYC202 (0)
›
Associations
(22)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Triple Negative Breast Cancer
No biomarker
Triple Negative Breast Cancer
CT7001
Sensitive: B - Late Trials
CT7001
Sensitive
:
B
CT7001
Sensitive: B - Late Trials
CT7001
Sensitive
:
B
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
CT7001
Sensitive: B - Late Trials
CT7001
Sensitive
:
B
CT7001
Sensitive: B - Late Trials
CT7001
Sensitive
:
B
IDH2 mutation
Glioma
IDH2 mutation
Glioma
TG02
Sensitive: C2 – Inclusion Criteria
TG02
Sensitive
:
C2
TG02
Sensitive: C2 – Inclusion Criteria
TG02
Sensitive
:
C2
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
SY-5609
Sensitive: C2 – Inclusion Criteria
SY-5609
Sensitive
:
C2
SY-5609
Sensitive: C2 – Inclusion Criteria
SY-5609
Sensitive
:
C2
IDH1 mutation
Glioma
IDH1 mutation
Glioma
TG02
Sensitive: C3 – Early Trials
TG02
Sensitive
:
C3
TG02
Sensitive: C3 – Early Trials
TG02
Sensitive
:
C3
HR positive
Hormone Receptor Positive Breast Cancer
HR positive
Hormone Receptor Positive Breast Cancer
CT7001
Sensitive: C3 – Early Trials
CT7001
Sensitive
:
C3
CT7001
Sensitive: C3 – Early Trials
CT7001
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
BTX-A51
Sensitive: C3 – Early Trials
BTX-A51
Sensitive
:
C3
BTX-A51
Sensitive: C3 – Early Trials
BTX-A51
Sensitive
:
C3
CDK7 overexpression
Cholangiocarcinoma
CDK7 overexpression
Cholangiocarcinoma
SY‑079
Sensitive: D – Preclinical
SY‑079
Sensitive
:
D
SY‑079
Sensitive: D – Preclinical
SY‑079
Sensitive
:
D
MYC amplification
Triple Negative Breast Cancer
MYC amplification
Triple Negative Breast Cancer
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
MYC amplification
Hepatocellular Cancer
MYC amplification
Hepatocellular Cancer
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
MYC amplification
Estrogen Receptor Positive Breast Cancer
MYC amplification
Estrogen Receptor Positive Breast Cancer
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
MYC amplification
Pancreatic Cancer
MYC amplification
Pancreatic Cancer
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
MYC amplification
Prostate Cancer
MYC amplification
Prostate Cancer
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
MYC amplification
Small Cell Lung Cancer
MYC amplification
Small Cell Lung Cancer
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
MYC amplification
Ovarian Cancer
MYC amplification
Ovarian Cancer
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
YPN-005
Sensitive: D – Preclinical
YPN-005
Sensitive
:
D
BRAF mutation
Colorectal Cancer
BRAF mutation
Colorectal Cancer
SY-5609
Sensitive: D – Preclinical
SY-5609
Sensitive
:
D
SY-5609
Sensitive: D – Preclinical
SY-5609
Sensitive
:
D
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
SY-5609
Sensitive: D – Preclinical
SY-5609
Sensitive
:
D
SY-5609
Sensitive: D – Preclinical
SY-5609
Sensitive
:
D
AR expression
Prostate Cancer
AR expression
Prostate Cancer
SY‑079
Sensitive: D – Preclinical
SY‑079
Sensitive
:
D
SY‑079
Sensitive: D – Preclinical
SY‑079
Sensitive
:
D
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
Q901
Sensitive: D – Preclinical
Q901
Sensitive
:
D
Q901
Sensitive: D – Preclinical
Q901
Sensitive
:
D
CD133 positive
Glioblastoma
CD133 positive
Glioblastoma
CYC065 + SY‑079
Sensitive: D – Preclinical
CYC065 + SY‑079
Sensitive
:
D
CYC065 + SY‑079
Sensitive: D – Preclinical
CYC065 + SY‑079
Sensitive
:
D
CD44 positive
Glioblastoma
CD44 positive
Glioblastoma
CYC065 + SY‑079
Sensitive: D – Preclinical
CYC065 + SY‑079
Sensitive
:
D
CYC065 + SY‑079
Sensitive: D – Preclinical
CYC065 + SY‑079
Sensitive
:
D
AR positive
Triple Negative Breast Cancer
AR positive
Triple Negative Breast Cancer
enzalutamide capsule + KRLS-017
Sensitive: D – Preclinical
enzalutamide capsule + KRLS-017
Sensitive
:
D
enzalutamide capsule + KRLS-017
Sensitive: D – Preclinical
enzalutamide capsule + KRLS-017
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login